Clinical trial
An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+)…
NCT00074997 · Janssen-Cilag Pty Ltd, Industry · Completed
Key facts
| NCT number | NCT00074997 |
|---|---|
| Title | An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection |
| Official title | A Randomized Phase II, Double-Blind, Controlled Trial to Evaluate the Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With Placebo or an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection |
| Lead sponsor | Janssen-Cilag Pty Ltd, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV-1 |
| Intervention type | Genetic, Other |
| Interventions | Placebo, OZ1, CD34+ cells |
| Enrollment | 1 |
| Start date | Dec 1, 2002 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Dec 31, 2003 |
| Last update posted | Jun 20, 2016 |
| Countries | Australia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: